E.V. Kruchinina(1), O.S. Gorenkova(1), A.V Glazkova(1), E.Yu. Polyakova(2), N.A. Kochina(3), E.V. Krasnoshchok(3), Y.Z. Zaydieva(1), E.N. Kareva(3,4), S.Yu. Serebrova(3,5), 1-Moscow Regional Research Institute of Obstetrics and Gynecology, Pokrovka str, 22A, Moscow, 101000, Russian Federation; 2-M.F. Vladimirsky Moscow Regional Research Clinical Institute, Shchepkina str., 61/2, Moscow, 129110, Russian Federation; 3-N.I. Pirogov Russian National Research Medical University (RNRMU), st. Ostrovitianova 1, Moscow, 117997, Russian Federation; 4-I.M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya str., 8/2, Moscow, 119991, Russian Federation; 5-Scientific Centre for Expert Evaluation of Medicinal Products, Petrovsky Blvd, 8/2, Moscow, 127051, Russian Federation E-mail: [email protected]

Introduction. Patients with surgical menopause are at risk for an osteopenic syndrome. For adequate medical correction of osteoporosis, it is necessary to clarify the mechanisms of the pathogenesis of this condition. It is known that osteoclasts, the activation of which is a recognized component of bone tissue destruction, are formed from circulating monocytes, and recently an active search is considered for ways to regulate this process. However, among monocytic marker molecules (the level of which varies in women with and without osteoporosis), there are no receptors or enzymes for steroid hormone metabolism. At the same time, the link between the level of sex steroids in women and the development of postmenopausal osteoporosis is obvious. The aim of the study. The level of transcription of possible target genes (estradiol and progesterone receptors, as well as vitamin D) was studied in peripheral blood mononuclear cells (PBMC). Methods. Densitometry, RT PCR. Results. It turned out that surgical menopause is characterized by manifestation of the osteopenic syndrome of the varying severity – from osteopenia to osteoporosis. At the same time, in patients with severe osteopenic syndrome (osteoporosis), there was a decrease in the expression of receptors for VDR, ER- alpha, and PR-A in PBMC by 11, 30 and 7 times, respectively (p≤0.05). Conclusion. Decrease in the expression of receptors for VDR, ER-alpha, and PR-A in PBMC can be regarded as one of the early pathogenesis of disorders of bone tissue metabolism caused by a deficiency of sex steroids.
osteoporosis, mRNA, RT-PCR, peripheral blood mononuclear cell (PBMC)

Список литературы: 
  1. Shalhoub V., Elliott G., Chiu L., Manoukian R., Kelley M., Hawkins N., Davy E., Shimamoto G., Beck J., Kaufman S.A., Van G., Scully S., Qi M., Grisanti M., Dunstan C., Boyle W.J., Lacey D.L. Characterization of osteoclast precursors in human blood,” British Journal of Haematology. 2000; 111 (2): 501–12.
  2. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nature Reviews Immunology. 2007; 7 (4): 292–304.
  3. Nicholson G.C., Malakellis M., Collier F.M., Cameron P.U., Holloway W.R., Gough T.J., Gregorio-King C., Kirkland M.A., Myers D.E. Induction of osteoclasts from CD14-positive human peripheral blood mononuclear cells by receptor activator of nuclear factor κB ligand (RANKL). Clinical Science. 2000; 99 (2): 133–40.
  4. Mosheimer B.A., Kaneider N.C., Feistritzer C., Sturn D.H., and Wiedermann C.J. Expression and function of RANK in human monocyte chemotaxis. Arthritis & Rheumatism. 2004; 50 (7): 2309–16.
  5. Li X., Qin L., Bergenstock M., Bevelock L.M., Novack D.V., and Partridge N.C. Parathyroid hormone stimulates osteoblastic expression of MCP-1 to recruit and increase the fusion of pre/osteoclasts. The J. of Biological Chemistry. 2007; 282 (45): 33098–106.
  6. Wright L.M., Maloney W., Yu X., Kindle L., Collin-Osdoby P., and Osdoby P. Stromal cell-derived factor-1 binding to its chemokine receptor CXCR4 on precursor cells promotes the chemotactic recruitment, development and survival of human osteoclasts. Bone. 2005; 36 (5): 840–53.
  7. Ishii M., Kikuta J., Shimazu Y., Meier-Schellersheim M., and Germain R.N. Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo. The J. of Experimental Medicine. 2010; 207 (13): 2793–8.
  8. Kikuta J., Ishii M. Osteoclast migration, differentiation and function: Novel therapeutic targets for rheumatic diseases. Rheumatology. 2013; 52 (20): 226–34.
  9. Daswani B., Khatkhatay M.I. «Omics» Signatures in Peripheral Monocytes from Women with Low BMD Condition. J. of Osteoporosis. 2018, Article ID 8726456, 7 pages.
  10. Salamanna F., Maglio M., Giavaresi G., Pagani S., Giardino R., and Fini M. In vitro method for the screening and monitoring of estrogen-deficiency osteoporosis by targeting peripheral circulating monocytes. Age (Dordrecht Netherlands). 2015; 37: 9819.
  11. Boyum A. Separation of leukocytes from blood and bone marrow. Scand. J. Lab. Investig. 1968; 21 (97): 1–9.
  12. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2[-δδC(T)] method. Methods. 2001; 25: 402–8.
  13. Hughes G.C. Progesterone and Autoimmune Disease. Autoimmun Rev. 2012; 11 (6–7): 502–14.
  14. Kareva E.N., Gankovskaja L.V., Shimanovskij N.L. Polovye steroidy i immunitet. Rossijskij immunologicheskij zhurnal. 2012; 1: 3–14. [Kareva, E.N., Gankovskaya, L.V., Shimanovsky, N.L.Sex steroids and immunity. Russian immunological journal, 2012; 1: 3–14 (in Russian)]
  15. Cvoro A., Tatomer D., Tee M.K., Zogovic T, Harris HA, Leitman DC. Selective estrogen receptor-beta agonists repress transcription of proinflammatory genes. Immunol. 2008; 180 (1): 630–6.
  16. Ray R., Novotny N.M., Crisostomo P.R., Lahm T., Abarbanell A., Meldrum D.R. Sex Steroids and Stem Cell Function. Mol. Med. 2008; 14 (7–8): 493–501.
  17. Gavali S., Gupta M.K., Daswani B., Wani M.R., Sirdeshmukh R., Khatkhatay M.I.Estrogen enhances human osteoblast survival and function via promotion of autophagy. Biochim Biophys Acta Mol Cell Res. 2019; pii: S0167–4889 (19) 30106-5.
  18. Kongsbak M., Levring T.B., Geisler C., and von Essen M. R. The Vitamin D Receptor and T Cell. Function. Front Immunol. 2013; 4: 148. Published online 2013 Jun 18.